Backed by an
Potential to expand to
other subtypes of NCL, such
as JNCL and INCL
There’s an urgent need for novel, therapeutic interventions of Batten disease. That’s where Polaryx® comes in.Learn More
Discover our unique methodology that allows Polaryx® to treat Batten disease - non-invasively.Learn More
Discover what’s holding back current treatments, and where Polaryx® excels.Learn More
Learn about the mechanism of action and drug repurposing strategy behind Polaryx®, and more.Learn More
Meet the team
With over 100 years of combined experience, we're ready to take the fight to Batten disease.Learn More
Learn more about Neuronal Ceroid Lipofuscinsosis (NCL), also known as Batten disease.Learn More
Polaryx Therapeutics Received Orphan Drug Designation From the European Medicines Agency (EMA) for the Treatment of Neuronal Ceroid Lipofuscinosis With PLX-200
Click "read more" now to view the press release.
Renowned pharmaceutical industry publication, Biopharma Dealmakers, has featured Polaryx® Therapeturics in their June 2017 edition. Click "read more" now to view the publication.
To introduce Polaryx® and its technology, GHP magazine has interviewed the Polaryx® team. Click now to see the June 2017 GHP magazine edition. Polaryx® is featured on pages 26-27.
Polaryx Therapeutics Receives Orphan Drug Designation From the U.S. FDA for PLX-200 for Rare Pediatric Disease
This new drug candidate will be used for the treatment of patients with Late Infantile Neuronal Ceroid Lipofuscinosis.
Polaryx Therapeutics Receives Orphan Drug Designation From the US FDA for the Treatment of Neuronal Ceroid Lipofuscinoses With PLX-100
Polaryx Therapeutics, Inc. is a biotech company developing patient-friendly oral small molecule therapeutics for Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL) and other forms of NCL, commonly known as Batten disease. Neuronal Ceroid Lipofuscinoses qualify as rare pediatric diseases under Section 529 of the Food, Drug, and Cosmetic Act.